Our survival investigation on an external HCC dataset from TCGA showed that, despite these samples representing a clinical context different from our own, the results were supportive, by revealing worse prognosis of tumors expressing high LGALS3 and LGALS3BP and low ALDH1A1. This evidence concerns the gene LGALS3 and hepatocellular carcinoma.